Figure 6.
Efficacy and immunogenicity of TC-83-based VLPV in a CBA/J-ML29 mouse model [57]. (A) Mice immunized with VLPV and ML29 (vaccine control) were fully protected against fatal challenge. (B) Mice immunized with ΔLGPfib VLPV induced stronger cell-mediated immunity in comparison with ML29- and LGPwt-immunized mice.